Special Populations and Pharmacogenetic Issues in Tuberculosis Drug Development and Clinical Research

Journal of Infectious Diseases

Volumn 211, Issue , 2015, Pages S115-S125

  McIlleron, Helen ^a   Abdel Rahman, Susan ^c,d,f   Dave, Joel Alex ^b   Blockman, Marc ^a   Owen, Andrew ^e  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Children's Mercy Hospital   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

children; diabetes; efficacy; HIV; pharmacogenetic; pharmacokinetic; pregnant women; safety; special population; tuberculosis

Indexed keywords

ISONIAZID; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; CHILD CARE; CLINICAL RESEARCH; DEVELOPING COUNTRY; DIABETES MELLITUS; DRUG DISPOSITION; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENETIC VARIABILITY; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLOMICS; MIXED INFECTION; MORBIDITY; MYCOBACTERIUM TUBERCULOSIS; PHARMACOGENETICS; POPULATION RESEARCH; PREGNANT WOMAN; PRIORITY JOURNAL; TUBERCULOSIS; CHILD; DRUG INTERACTION; FEMALE; MEDICAL RESEARCH; PHYSIOLOGY; PREGNANCY; PROCEDURES;

ANTITUBERCULAR AGENTS; BIOMEDICAL RESEARCH; CHILD; DRUG INTERACTIONS; FEMALE; HUMANS; PHARMACOGENETICS; PREGNANCY; TUBERCULOSIS;

EID: 84937437343     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu600     Document Type: Article

References (105)

1. FDA action plan to enhance the collection and availability of demographic subgroup data. August 2014. http://www.fda.gov/downloads/RegulatoryInformation/Legislation/FederalFoodDrugandCosmetic ActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/UCM410474. pdf. Accessed 11 September 2014.
2. Pediatric Research Equity Act of 2007. Pub L No 110-85, 121 Stat 823. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM049870.pdf. Accessed 10 September 2014.
3. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use. 2006.
4. Tishkoff SA, Reed FA, Friedlaender FR, et al. The genetic structure and history of Africans and African Americans. Science 2009; 324: 1035-44.
5. Gupta A, Nayak U, Ram M, et al; Byramjee Jeejeebhoy Medical College-Johns Hopkins University Study Group. Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005. Clin Infect Dis 2007; 45:241-9.
6. World Health Organization. Global tuberculosis report 2013. WHO/HTM/TB/2013. http://www.who.int/tb/publications/global-report/en/. Accessed 3 June 2013.
7. Dodd PJ, Gardiner E, Coghlan R, Seddon JA. Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modeling study. Lancet Glob Health 2014; 2:453-9.
8. Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the prechemotherapy era. Int J Tuberc Lung Dis 2004; 8:392-402.
9. Abdel-Rahman SM, Kearns GL. Technical study report prepared for theWorld Health Organization (WHO). CPMT project 08-010. Pharmacokinetic analyses of fixed-dose drug combinations for pediatric tuberculosis. Geneva: WHO, 2009.
10. Abdel-Rahman SM, Kearns GL. Technical study report prepared for theWorld Health Organization (WHO). CPMT project 09-010. Pharmacokinetic simulations of a fixed-dose ethambutol formulation for pediatric tuberculosis. Geneva: WHO, 2009.
11. Goldman JL, Kearns GL, Abdel-Rahman SM. Pharmacological considerations of antitubercular agents in children. Prog Respir Res 2011; 40:161-75.
12. Shaddy RE, Denne SC. The Committee on Drugs and Committee of Pediatric Research. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 2010; 125:850-60.
13. Royal College of Paediatrics and Child Health (RCPCH) Ethics Advisory Committee. Guidelines for the ethical conduct of medical research involving children. Arch Dis Child 2000; 82:117-82.
14. International Conference on Harmonization. Guidance on E11 clinical investigation of medicinal products in the pediatric population. Fed Regist 2000; 65:19777-81.
15. US Department of Health and Human Services, Food and Drug Administration (FDA). Draft guidance for industry. General consideration for pediatric pharmacokinetic studies for drugs and biological products. Rockville, MD: FDA, 1998.
16. Abdel-Rahman SM, Wells T, Reed M, Kearns GL. Considerations in the rational design and conduct of pediatric clinical pharmacology trials: avoiding the problems and pitfalls. Clin Pharmacol Ther 2007; 81:483-94.
17. Anderson BJ, Holford NHG. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009; 24:25-36.
18. Ginsberg G, Hattis D, Sonawane B, et al. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci 2002; 66:185-200.
19. Rodriguez W, Selen A, Avant D, et al. Improving Pediatric Dosing Through Pediatric Initiatives: What We Have Learned. Pediatrics 2008; 121:530-9.
20. Notterman DA, Nardi M, Saslow JG. Effect of dose formulation on isoniazid absorption in two young children. Pediatrics 1986; 77:850-2.
21. Weiner M, Savic RM, Mac Kenzie WR, et al. Tuberculosis Trials Consortium PREVENT TB Pharmacokinetic Group. Rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection. J Ped Infect Dis 2014; 3:132-45.
22. Gorenberg H, White A. Off the pedestal and into the arena: toward including women in experimental protocols. Rev Law Soc Change 1991; 19:205-46.
23. National Institutes of Health Revitalization Act of 1993. Pub L No. 103-43, 107 Stat 122.
24. Berlin JA, Ellenberg SS. Inclusion of women in clinical trials. BMC Med 2009; 7:56.
25. Goldkind SF, Sahin L, Gallauresi B. Enrolling pregnant women in research-lessons from the H1N1 influenza pandemic. N Engl J Med 2010; 362:2241-3.
26. US Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research. Guidance for industry. Pharmacokinetics in pregnancy-study design, data analysis and impact on dosing and labelling. Rockville, MD: FDA, 2004: 5.
27. Rodger MA, Makropoulos D, Walker M, Keely E, Karovitch A, Wells PS. Participation of PregnantWomen in Clinical Trials:Will They Participate and Why? Am J Perinatol 2003; 20:69-76.
28. Mohanna K, Tunna K. Withholding consent to participate in clinical trials: decisions of pregnant women. Br J Obstet Gynaecol 1999; 106:892-7.
29. Kass NE, Taylor HA, King PA. Harms of excluding pregnant women from clinical research: the case of HIV-infected pregnant women. J Law Med Ethics 1996; 24:36-46.
30. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine-and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300:530-9.
31. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697-706.
32. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471-81.
33. Havlir DV, Kendall MA, Ive P, et al. AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365:1482-91.
34. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8:516-23.
35. McIlleron H, Khoo SH. Interactions between antituberculosis and antiretroviral agents. In: Donald PR, Van Helden PD, eds. Progress in respiratory research: antituberculosis chemotherapy. Vol 40. Basel, Switzerland: Karger Publishing, 2011: 191-202.
36. Zhang C, Denti P, Decloedt E, et al. Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin. Br J Clin Pharmacol 2012; 73:758-67.
37. Ren Y, Nuttall JJ, Eley BS, et al. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2009; 50:439-43.
38. Cohen K, Grant A, Dandara C, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009; 14:687-95.
39. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 2006; 20:131-2.
40. Ngaimisi E, Mugusi S, Minzi O, et al. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther 2011; 90:406-13.
41. McIlleron H, Ren Y, Nuttall J, et al. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. Antivir Ther 2011; 16:417-21.
42. La Porte CJ, Colbers EP, Bertz R, et al. Pharmacokinetics of adjusteddose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48:1553-60.
43. Nijland HM, L'homme RF, Rongen GA, et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 2008; 22:931-5.
44. Haas DW, Koletar SL, Laughlin L, et al; A5213 StudyTeam. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr 2009; 50:290-3.
45. Decloedt EH, McIlleron H, Smith P, Merry C, Orrell C, Maartens G. Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets. Antimicrob Agents Chemother 2011; 55:3195-200.
46. Frohoff C, MoodleyM, Fairlie L, et al. Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS One 2011; 6:e17273.
47. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev 2007: CD005159.
48. Moultrie H, McIlleron H, Sawry S, et al. Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir. J Antimicrob Chemother 2014:pii:dku382.
49. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002; 1:153-61.
50. O'Donnell MR, Padayatchi N, Master I, Osburn G, Horsburgh CR. Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. Int J Tuberc Lung Dis 2009; 13:855-61.
51. Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, Satti H. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS One 2009; 4:e7186.
52. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008; 5:e152.
53. Pablos-Mendez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 1997; 87:574-9.
54. Moutschen MP, Scheen AJ, Lefebvre PF. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabete Metab 1992; 18:187-201.
55. Chang FY, Shaio MF. Decreased cell-mediated immunity in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1995; 28:137-46.
56. Chang FY, Shaio MF. Respiratory burst activity of monocytes from patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1995; 29:121-7.
57. Saiki O, Negoro S, Tsuyuguchi I, Yamamura Y. Depressed immunological defence mechanisms in mice with experimentally induced diabetes. Infect Immun 1980; 28:127-31.
58. Banerjee S, Banerjee M. Diabetes and tuberculosis interface. J Indian Med Assoc 2005; 103:318, 320, 322 passim.
59. Wang CS, Yang CJ, Chen HC, et al. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect 2009; 137:203-10.
60. Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg 2009; 80:634-9.
61. Morsy AM, Zaher HH, Hassan MH, Shouman A. Predictors of treatment failure among tuberculosis patients under DOTS strategy in Egypt. East Mediterr Health J 2003; 9:689-701.
62. Bashar M, Alcabes P, Rom WN, Condos R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest 2001; 120:1514-9.
63. Fisher-Hoch SP, Whitney E, McCormick JB, et al. Type 2 diabetes and multidrug-resistant tuberculosis. Scand J Infect Dis 2008; 40: 888-93.
64. Banu Rekha VV, Balasubramanian R, Swaminathan S, et al. Sputum conversion at the end of intensive phase of category-1 regimen in the treatment of pulmonary tuberculosis patients with diabetes mellitus or HIV infection: An analysis of risk factors. Indian J Med Res 2007; 126:452-8.
65. Singla R, Khan N, Al-Sharif N, Ai-Sayegh MO, Shaikh MA, Osman MM. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. Int J Tuberc Lung Dis 2006; 10:74-9.
66. Swai AB, McLarty DG, Mugusi F. Tuberculosis in diabetic patients in Tanzania. Trop Doct 1990; 20:147-50.
67. Olmos P, Donoso J, Rojas N, et al. Tuberculosis and diabetes mellitus: a longitudinal-retrospective study in a teaching hospital. Rev Med Chil 1989; 117:979-83.
68. Leung CC, Lam TH, Chan WM, et al. Diabetic control and risk of tuberculosis: a cohort study. Am J Epidemiol 2008; 167:1486-94.
69. Baolu OK, Bacakolu F, Cok G, Sayiner A, Ate M. The oral glucose tolerance test in patients with respiratory infections. Monaldi Arch Chest Dis 1999; 54:307-10.
70. Oluboyo PO, Erasmus RT. The significance of glucose intolerance in pulmonary tuberculosis. Tubercle 1990; 71:135-8.
71. Ruslami R, Van Crevel R. Diabetes mellitus and tuberculosis treatment. In: Donald PR, van Helden PD, eds. Antituberculosis chemotherapy. Vol 40. Basel, Switzerland: Karger Publishing, 2011:203-12.
72. World Health Organisation. Overweight and obesity. http://www.who. int/gho/ncd/risk-factors/overweight/en/index.htm. Accessed 1 November 2011.
73. Samaras K. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection. J Antimicrob Chemother 2008; 61:238-45.
74. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 proteaseinhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-9.
75. Dagogo-Jack S. HIV therapy and diabetes risk. Diabetes Care 2008; 31:1267-8.
76. Dave JA, Lambert EV, Badri M, West S, Maartens G, Levitt NS. Effect of nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy on dysglycemia and insulin sensitivity in South African HIV-infected patients. J Acquir Immune Defic Syndr 2011; 57:284-9.
77. International Diabetes Federation. Diabetes: facts and figures. http://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures. Accessed 23 June 2014.
78. US Department of Health and Human Services, Food and Drug Administration (FDA). Guidance for industry. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. Rockville, MD: FDA, 2003.
79. US Department of Health and Human Services, Food and Drug Administration. Draft guidance for industry. Pharmacokinetics in patients with impaired renal function: study design, data analysis, and impact on dosing and labeling. Rockville, MD: FDA, 2010.
80. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of interand intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998; 8:283-9.
81. Ellard GA, Gammon PT. Pharmacokinetics of isoniazid metabolism in man. J Pharmacokinet Biopharm 1976; 4:83-113.
82. Sun F, Chen Y, Xiang Y, Zhan S. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2008; 12:994-1002.
83. Chigutsa E, Visser ME, Swart EC, et al. The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications. Antimicrob Agents Chemother 2011; 55:4122-7.
84. Weiner M, Peloquin C, Burman W, et al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother 2010; 54:4192-200.
85. Hartkoorn RC, Kwan WS, Shallcross V, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 2010; 20:112-20.
86. Martin P, Riley R, Back DJ, Owen A. Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. Br J Pharmacol 2008; 153: 805-19.
87. Lamba J, Lamba V, Strom S, Venkataramanan R, Schuetz E. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 2008; 36:169-81.
88. Schipani A, Siccardi M, D'Avolio A, et al. Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother 2010; 54:5242-50.
89. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997; 247:625-34.
90. Vyhlidal CA, Gaedigk R, Leeder JS. Nuclear receptor expression in fetal and pediatric liver: correlation with CYP3A expression. Drug Metab Dispos 2006; 34:131-7.
91. Zhu R, Kiser JJ, Seifart HI, et al. The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J Clin Pharmacol 2012; 52:511-9.
92. Hemauer SJ, Nanovskaya TN, Abdel-Rahman SZ, Patrikeeva SL, Hankins GD, Ahmed MS. Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms. Biochem Pharmacol 2010; 79:921-5.
93. Dheenadhayalan V, Shanmugalakshmi S, Vani S, et al. Association of interleukin-10 cytokine expression status with HLA non-DRB1∗02 and Mycobacterium bovis BCG scar-negative status in south Indian pulmonary tuberculosis patients. Infect Immun 2001; 69:5635-42.
94. Kim HS, Park MH, Song EY, et al. Association of HLA-DR and HLADQ genes with susceptibility to pulmonary tuberculosis in Koreans: preliminary evidence of associations with drug resistance, disease severity, and disease recurrence. Hum Immunol 2005; 66:1074-81.
95. Shi GL, Hu XL, Yang L, Rong CL, Guo YL, Song CX. Association of HLA-DRB alleles and pulmonary tuberculosis in North Chinese patients. Genet Mol Res 2011; 10:1331-6.
96. Yuliwulandari R, Sachrowardi Q, Nakajima H, et al. Association of HLA-A,-B, and-DRB1 with pulmonary tuberculosis in western Javanese Indonesia. Hum Immunol 2010; 71:697-701.
97. Denholm JT, McBryde ES, Eisen DP. Mannose-binding lectin and susceptibility to tuberculosis: a meta-analysis. Clin Exp Immunol 2010; 162:84-90.
98. Means TK, Wang S, Lien E, Yoshimura A, Golenbock DT, Fenton MJ. Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol 1999; 163:3920-7.
99. Morahan G, Kaur G, Singh M, et al. Association of variants in the IL12B gene with leprosy and tuberculosis. Tissue Antigens 2007; 69(suppl 1):234-6.
100. Shibasaki M, Yagi T, Yatsuya H, et al. An influence of Interferongamma gene polymorphisms on treatment response to tuberculosis in Japanese population. J Infect Dis 2009; 58:467-9.
101. Xue Y, Zhao ZQ, Wang HJ, et al. Toll-like receptors 2 and 4 gene polymorphisms in a southeastern Chinese population with tuberculosis. Int J Immunogenet 2010; 37:135-8.
102. Denholm JT, McBryde ES. P2X7 A1513 polymorphisms and tuberculosis susceptibility. Respirology 2012; 17:191.
103. Huang Y, PaxtonWA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2:1240-3.
104. Donald PR, Parkin DP, Seifart HI, et al. The influence of dose and Nacetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol 2007; 63:633-9.
105. Burns DK, Hughes AR, Power A, Wang SJ, Patterson SD. Designing pharmacogenomic studies to be fit for purpose. Pharmacogenomics 2010; 11:1657-67.